1. Medtech Insight
  2. >>Business

Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

Upgrade could boost Dexcom’s competitive positioning against Abbott’s Libre 3 Plus.

 
• By Shubham Singh

Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.

The new device is expected to enhance patient experience by extending wear time beyond its current 10-day G7 sensor.
Key Takeaways
  • Dexcom expects to launch its 15-day G7 sensor in the second half of 2025, pending US FDA approval. The company is prioritizing insurance coverage and pump integration before a full rollout. 

      Dexcom is gearing up to launch its 15-day sensor in the second half of this year, pending authorization from the US Food and Drug Association. However, questions remain about the level of insurance coverage the new product will receive, especially in comparison to competitors like Abbott’s FreeStyle Libre 3 Plus, which also offers a 15-day wear period.

      More from Business

      Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

       
      • By Marion Webb

      Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

      Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

       
      • By Shubham Singh

      Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

      Deals Shaping The Medtech And Diagnostics Industries, June 2025

       
      • By Medtech Insight Team

      An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

      HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

       
      • By Natasha Barrow

      Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

      More from Policy & Regulation

      HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

       
      • By Natasha Barrow

      Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

      EUDAMED Notice Anticipated By September As Commission Optimizes Operations

       
      • By Amanda Maxwell

      The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

      From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

       
      • By Marion Webb

      Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.